Expert system

Expert Systems Celebrates a Milestone with Eilean Therapeutics: Initiation of First-in-Patient Trial of Balamenib, a Selective Best-in-Class Menin Inhibitor

Retrieved on: 
Wednesday, March 13, 2024
OrbiMed, AML, Drug discovery, Partnership, CBO, AI, Therapy, CTN, Safety, TGA, Expert system, Medical device

"Balamenib has a highly differentiated pre-clinical profile which indicates important advantages over molecules in the same class in safety, tolerability and feasibility of outpatient treatment," commented Bill Farley, CBO at Expert Systems.

Key Points: 
  • "Balamenib has a highly differentiated pre-clinical profile which indicates important advantages over molecules in the same class in safety, tolerability and feasibility of outpatient treatment," commented Bill Farley, CBO at Expert Systems.
  • "We are proud that our comprehensive hybrid AI-based platform has helped accelerate the development of a new promising & safe treatment for AML."
  • Supported by Orbimed, Torrey Pines Investment, and Dr. John C. Byrd, Eilean Therapeutics is committed to leading the development of innovative therapies that significantly enhance treatment outcomes in both hematologic and solid malignancies.
  • This effort is bolstered by leveraging Expert Systems' cutting-edge AI platform to speed up the discovery and development process.

Expert Systems Expands Partnership with Eilean Therapeutics and Joins Its Best-in-Class PTPN2 Inhibitor Program

Retrieved on: 
Tuesday, March 12, 2024
Ness, PTPN2, CBO, Therapy, Expert system, Safety, Pharmaceutical industry

ROCKVILLE, Md., March 12, 2024 /PRNewswire/ -- Expert Systems, a leader in AI-enabled drug discovery, announces the expansion of the collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program, which Eilean has recently acquired from Ness Therapeutics Inc (Ness) in an all-equity transaction.

Key Points: 
  • ROCKVILLE, Md., March 12, 2024 /PRNewswire/ -- Expert Systems, a leader in AI-enabled drug discovery, announces the expansion of the collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program, which Eilean has recently acquired from Ness Therapeutics Inc (Ness) in an all-equity transaction.
  • "Eilean's lead PTPN2 inhibitor molecules demonstrate exceptional efficacy, selectivity, oral bioavailability and a good safety profile," commended Bill Farley, CBO at Expert Systems.
  • "We're proud to be Eilean's partner & leverage our cutting-edge AI platform to help advance a new pipeline of best-in-class immuno-oncological therapy solutions with an improved safety and tolerability profile."

Shield AI Selected by NAVAIR PMA-281 to Integrate Hivemind AI Pilot onto eighth aircraft: the Kratos BQM-177A

Retrieved on: 
Tuesday, March 12, 2024
SAN, DCA, Expert system, Aviation, GPS, F-16, Learning, Collier Trophy, OEM, Shield AI, Aircraft, DARPA, Navy, NAVAIR, Airline

SAN DIEGO, March 12, 2024 /PRNewswire/ -- Shield AI, the defense technology company building the world's best AI pilot, today announced it has been selected by NAVAIR PMA-281 to integrate its AI Pilot onto the Kratos BQM-177A to enable advanced AI-based autonomy.

Key Points: 
  • SAN DIEGO, March 12, 2024 /PRNewswire/ -- Shield AI, the defense technology company building the world's best AI pilot, today announced it has been selected by NAVAIR PMA-281 to integrate its AI Pilot onto the Kratos BQM-177A to enable advanced AI-based autonomy.
  • "This will be the eighth different type of aircraft integration we've done; it will be the fourth jet aircraft.
  • Kratos has been a terrific partner in rolling out our AI pilot onto jet aircraft," said Brandon Tseng, Shield AI's President/Cofounder, a mechanical engineer, and a former U.S. Navy SEAL.
  • Shield AI's innovative technical approach for the Navy contract employs an AI architecture that starts with foundational autonomy behaviors.

Expert Systems Celebrates Completion of Single Dose Studies and Start of Multiple Human Dosing for Lomonitinib, a Selective Pan-FLT3/IRAK4 Inhibitor, Achieved in Just 3 Years

Retrieved on: 
Friday, February 23, 2024
Expert system, OrbiMed, Drug discovery, Therapy, CBO, Partnership

"Lomonitinib has demonstrated an exceptional safety profile, with no significant adverse events reported at doses achieving robust target engagement.

Key Points: 
  • "Lomonitinib has demonstrated an exceptional safety profile, with no significant adverse events reported at doses achieving robust target engagement.
  • This positions it as a leading best-in-class candidate for the treatment of FLT3-mutated AML," commented Bill Farley, CBO at Expert Systems.
  • "We are proud that our comprehensive hybrid AI-based platform has helped advance a new treatment like lomonitinib to clinical trials in just 3 years."
  • This effort is bolstered by leveraging Expert Systems' cutting-edge AI platform to speed up the discovery and development process.

Expert Systems Celebrates Accelerated Start of Human Dosing for Eiletoclax, a Selective BCL2 Inhibitor, Achieved in Just 3 Years

Retrieved on: 
Wednesday, February 21, 2024
Expert system, OrbiMed, Drug discovery, BCL2, Bone marrow, Therapy, CBO, Pharmaceutical industry

This development marks a pivotal advance in the battle against hematologic malignancies, with eiletoclax gaining approval from the Human Research Ethics Committee in Australia for Phase 1 trials.

Key Points: 
  • This development marks a pivotal advance in the battle against hematologic malignancies, with eiletoclax gaining approval from the Human Research Ethics Committee in Australia for Phase 1 trials.
  • "Eiletoclax stands out for its exceptional potency and selectivity against BCL2, along with an improved safety profile over venetoclax, underscoring its promise as a best-in-class cancer treatment," commented Bill Farley, CBO at Expert Systems.
  • "We're very proud that our comprehensive hybrid AI-based platform has helped advance a new treatment like eiletoclax to clinical trials."
  • This effort is bolstered by leveraging Expert Systems' cutting-edge AI platform to speed up the discovery and development process.

EXPERT SYSTEMS FACILITATES RAPID ADVANCEMENT OF GROUNDBREAKING COVID-19 TREATMENT, TRX01, TO CLINICAL TRIALS WITHIN TWO YEARS

Retrieved on: 
Tuesday, February 13, 2024
Therapy, ESI, Safety, Expert system, SARS-CoV-2, CBO, Pharmacokinetics

ROCKVILLE, Md., Feb. 13, 2024 /PRNewswire/ -- Expert Systems Inc., a private company (ESI), announces the initiation of a first-in-human trial of TRX01 by their partner Trawsfynydd Therapeutics, a private company.

Key Points: 
  • ROCKVILLE, Md., Feb. 13, 2024 /PRNewswire/ -- Expert Systems Inc., a private company (ESI), announces the initiation of a first-in-human trial of TRX01 by their partner Trawsfynydd Therapeutics, a private company.
  • Expert Systems deployed their accelerator platform to engineer this cutting-edge protease inhibitor targeting the SARS-CoV-2 viral main protease (3CL, Mpro) in less than two years.
  • The Phase 1 clinical trial aims to evaluate TRX01's safety, tolerability, and pharmacokinetics in healthy individuals, laying the foundation for potential regulatory approval and broad accessibility for this much needed therapeutic.
  • "Expert Systems' AI-driven rational design methodologies have played a pivotal role in creating superior therapeutics, eliminating the necessity for ritonavir co-administration, marking a major stride in combating this lethal viral disease," commented Bill Farley, CBO at Expert Systems.

Investigators from John Byrd's Lab at University of Cincinnati Presented Non-Clinical Summary Data for The Best-in-Class Selective BCL2 Inhibitor Clinical Candidate Developed by Eilean Therapeutics in Collaboration with ChemDiv

Retrieved on: 
Wednesday, December 13, 2023
BCL2, SAN, Expert system, Chemical Diversity, CYP3A, Eilean Donan, Pharmacology, University, Cancer, Safety, University of Cincinnati, Venetoclax, Pharmaceutical industry

"A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax" was presented by collaborators from University of Cincinnati (Ohio), Molsoft LLC, Expert Systems Inc of San Diego California, and Eilean Therapeutics LLC of Dover, Delaware.

Key Points: 
  • "A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax" was presented by collaborators from University of Cincinnati (Ohio), Molsoft LLC, Expert Systems Inc of San Diego California, and Eilean Therapeutics LLC of Dover, Delaware.
  • The presentation highlighted best-in-class potency and selectivity against BCL2, a key pro-survival protein that is overexpressed in many cancers.
  • This clinical candidate demonstrated an equivalent in vivo anti-tumor efficacy as venetoclax in both B cell and myeloid malignancy cell lines and in vivo models.
  • Compared to venetoclax, the candidate exhibits significantly less suppression of non-malignant immune cell populations, a result that signals superior selectivity and improved safety profile.

ChemDiv Presented Non-Clinical Summary Data for The Best-in-Class Selective FLT3 Clinical Candidate at the 65th ASH Annual Meeting and Exposition with Its Partners and Sponsors

Retrieved on: 
Tuesday, December 12, 2023
Immunocompetence, Safety, SAN, Expert system, Chemical Diversity, Eilean Donan, Pharmacology, FLT3, University, Survival, AML, University of Cincinnati, Pharmaceutical industry

SAN DIEGO, Dec. 12, 2023 /PRNewswire/ -- ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces the presentation of non-clinical summary data for the best-in-class selective FLT3 clinical candidate at the 65th ASH Annual Meeting and Exposition in San Diego, CA.

Key Points: 
  • SAN DIEGO, Dec. 12, 2023 /PRNewswire/ -- ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces the presentation of non-clinical summary data for the best-in-class selective FLT3 clinical candidate at the 65th ASH Annual Meeting and Exposition in San Diego, CA.
  • "Therapeutic Targeting of FLT3 gatekeeper mutation with E2082-0047 in traditional and a novel Immunocompetent murine adoptive transfer model of AML" was presented by collaborators from University of Cincinnati, Ohio, Molsoft LLC and Expert Systems Inc of San Diego, California, and Eilean Therapeutics LLC from Dover, Delaware.
  • The presentation highlighted best-in-class potency and selectivity against gatekeeper resistant FLT-mutant AML and compelling survival benefit superior to gilteritinib in a fully immunocompetent Nmp1CAFLT3ITD-F692L AML adoptive transfer model, supporting the clinical candidate's ongoing clinical development.
  • In collaboration with rational design groups of Molsoft and Expert Systems, John Byrd's lab at University of Cincinnati, ChemDiv deployed a muti-targeting/multi-property optimization approach to achieve a 400-1000x selectivity of the resulting clinical candidate, which translated in best-in-class efficacy, safety, tolerability and developable pharmacology advantages delivered to partners at Eilean Therapeutics LLC.

How AI is Transforming Drug Discovery: Bio-IT World Europe Participants to Share Groundbreaking Advances 29-30 November in London

Retrieved on: 
Monday, November 6, 2023
Digital, China Earthquake Networks Center, AstraZeneca, Expert system, Health care, Government, LDN, Conference, Organization, Research, Drug development, Clarivate, Artificial intelligence, MOSAIC, Medicine, Drug discovery, Machine learning, Personalized medicine, RDN, AI, Potential, D, Queen Mary University of London, Medical device, Cancer

LONDON, Nov. 6, 2023 /PRNewswire-PRWeb/ -- The life sciences profession is in the midst of a profound transformation, guided by the revolutionary force of artificial intelligence (AI), and especially predictive and generative AI models. These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.

Key Points: 
  • These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.
  • "The bio-IT community has always been at the forefront of leveraging AI with the important goal of increasing therapeutic efficacy."
  • In parallel, generative AI refines molecular design with exquisite precision, drastically curtailing the time and resources necessary for drug development.
  • "As general interest in AI explodes, our distinguished speakers have valuable information to share about its evolving role in precision medicine."

EAI Signs Agreement on AI Education Cooperation with Lenovo Hong Kong

Retrieved on: 
Wednesday, September 13, 2023
Learning, Expert system, Lenovo, STEAM, EAI, Education, Information technology, Stanford University, All, Teaching, Curriculum, Research, Creativity, School, Student, HKEX, Stanford University centers and institutes, Artificial intelligence, Tutoring, Medical device, Mainland China, AI

Fan Ho, General Manager (Hong Kong and Macau) of Lenovo Hong Kong and Mr. Jonathan Cheng, Head of Strategy and Sales (Hong Kong and Macau) of Lenovo Hong Kong

Key Points: 
  • Fan Ho, General Manager (Hong Kong and Macau) of Lenovo Hong Kong and Mr. Jonathan Cheng, Head of Strategy and Sales (Hong Kong and Macau) of Lenovo Hong Kong
    EAI has established a cooperation plan with Lenovo Hong Kong whereby it will become its partner in an AI education plan, under which both parties will jointly launch a series of AI laboratory equipment
    and related courses specifically designed for primary and secondary schools.
  • The cooperation arrangement includes co-marketing with Lenovo Hong Kong of a series of AI laboratory equipment and related courses, which will be sold to primary and secondary schools through Lenovo Hong Kong.
  • With the widespread use of AI in various fields and sectors, the Hong Kong government has explicitly expressed support to schools to promote AI education.
  • The education sector has been vigorously promoting STEAM education, and the widespread promotion and popularization of AI education have become imperative.